A Phase 1 / 2a Study of In-situ REIC/Dkk-3 Therapy in Patients With Localized Prostate Cancer (MTG-REIC-PC003)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Ad5 SGE DKK3 gene therapy-Momotaro (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Momotaro-Gene
- 03 Sep 2020 Status changed from active, no longer recruiting to completed.
- 22 Oct 2019 Planned End Date changed from 1 Jun 2019 to 1 Mar 2020.
- 07 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.